← Back to Search

PET MRI for Liver Cancer (PETMRIinHCC Trial)

N/A

Waitlist Available

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adults (age ≥ 18-years old)

Histological or radiological diagnosis of HCC (AASLD guidelines)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

PETMRIinHCC Trial Summary

This trial is studying how well 18F-FDG PET/MRI works in predicting HCC recurrence after liver transplant.

Who is the study for?

This trial is for adults over 18 with a diagnosis of early-stage Hepatocellular Carcinoma (HCC) who are listed for liver transplantation at UHN. Participants must be willing to give informed consent and able to undergo PET/MRI scans. They should also be enrolled in a ctDNA study.Check my eligibility

What is being tested?

The trial is testing the use of an imaging technique called 18F-FDG PET/MRI to predict HCC recurrence after liver transplantation. It aims to see if this method can indicate tumor behavior and link it with circulating tumor DNA in the blood, potentially influencing transplant eligibility criteria.See study design

What are the potential side effects?

Since the intervention involves only non-invasive imaging techniques like PET and MRI, there are minimal side effects which may include discomfort during scanning or reactions related to contrast agents used.

PETMRIinHCC Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

My liver cancer diagnosis was confirmed by lab tests or scans.

PETMRIinHCC Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

18F-FDG PET/MRI results can identify aggressive HCC behavior and recurrence post transplant

Secondary outcome measures

18F-FDG PET/MRI are related to presence of circulating tumor DNA in plasma

18F-FDG PET/MRI can predict HCC's poor tumoral differentiation

PETMRIinHCC Trial Design

1Treatment groups

Experimental Treatment

Group I: PET MRI ArmExperimental Treatment1 Intervention

Patient enrolled in the study will have a PET MRI exam scheduled before transplant

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor

1,468 Previous Clinical Trials

484,470 Total Patients Enrolled

3 Trials studying Liver Cancer

51 Patients Enrolled for Liver Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still opportunities for individuals to enroll in this clinical experiment?

"According to information on clinicaltrials.gov, this medical study is no longer actively recruiting patients; the trial was initially published in August 2018 and last updated in October 2020. Despite its termination, there are 3400 other trials currently open for enrollment at this time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Relationship Between 18FDG PET/MRI Patterns and ctDNA to Predict HCC Recurrence After Liver Transplantation

2018. "Relationship Between 18FDG PET/MRI Patterns and ctDNA to Predict HCC Recurrence After Liver Transplantation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03839706.

All > Liver Transplant